Top

Published in:

01-04-2012 | Research Paper

Ubiquitous Brms1 expression is critical for mammary carcinoma metastasis suppression via promotion of apoptosis

Authors: Leah M. Cook, Xuemei Cao, Alexander E. Dowell, Michael T. Debies, Mick D. Edmonds, Benjamin H. Beck, Robert A. Kesterson, Renee A. Desmond, Andra R. Frost, Douglas R. Hurst, Danny R. Welch

Published in: Clinical & Experimental Metastasis | Issue 4/2012

Abstract

Morbidity and mortality of breast cancer patients are drastically increased when primary tumor cells are able to spread to distant sites and proliferate to become secondary lesions. Effective treatment of metastatic disease has been limited; therefore, an increased molecular understanding to identify biomarkers and therapeutic targets is needed. Breast cancer metastasis suppressor 1 (BRMS1) suppresses development of pulmonary metastases when expressed in a variety of cancer types, including metastatic mammary carcinoma. Little is known of Brms1 function throughout the initiation and progression of mammary carcinoma. The goal of this study was to investigate mechanisms of Brms1-mediated metastasis suppression in transgenic mice that express Brms1 using polyoma middle T oncogene-induced models. Brms1 expression did not significantly alter growth of the primary tumors. When expressed ubiquitously using a β-actin promoter, Brms1 suppressed pulmonary metastasis and promoted apoptosis of tumor cells located in the lungs but not in the mammary glands. Surprisingly, selective expression of Brms1 in the mammary gland using the MMTV promoter did not significantly block metastasis nor did it promote apoptosis in the mammary glands or lung, despite MMTV-induced expression within the lungs. These results strongly suggest that cell type-specific over-expression of Brms1 is important for Brms1-mediated metastasis suppression.

Available only for authorised users

Siegel R, Ward E, Brawley O et al (2011) Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 61:212–236PubMedCrossRef

Cook LM, Hurst DR, Welch DR (2011) Metastasis suppressors and the tumor microenvironment. Semin Cancer Biol 21:113–122PubMedCrossRef

Hurst DR, Welch DR (2011) Metastasis suppressor genes: at the interface between the environment and tumor cell growth. Int Rev Cell Mol Biol 286:107–180PubMedCrossRef

Seraj MJ, Samant RS, Verderame MF et al (2000) Functional evidence for a novel human breast carcinoma metastasis suppressor, BRMS1, encoded at chromosome 11q13. Cancer Res 60:2764–2769PubMed

Shevde LA, Samant RS, Goldberg SF et al (2002) Suppression of human melanoma metastasis by the metastasis suppressor gene, BRMS1. Exp Cell Res 273:229–239PubMedCrossRef

Zhang S, Lin QD, Di W (2006) Suppression of human ovarian carcinoma metastasis by the metastasis-suppressor gene, BRMS1. Int J Gynecol Cancer 16:522–531PubMedCrossRef

Smith PW, Liu Y, Siefert SA et al (2009) Breast cancer metastasis suppressor 1 (BRMS1) suppresses metastasis and correlates with improved patient survival in non-small cell lung cancer. Cancer Lett 276:196–203PubMedCrossRef

Saunders MM, Seraj MJ, Li ZY et al (2001) Breast cancer metastatic potential correlates with a breakdown in homospecific and heterospecific gap junctional intercellular communication. Cancer Res 61:1765–1767PubMed

Kapoor P, Saunders MM, Li Z et al (2004) Breast cancer metastatic potential: correlation with increased heterotypic gap junctional intercellular communication between breast cancer cells and osteoblastic cells. Int J Cancer 111:693–697PubMedCrossRef

10.

Bodenstine TM, Vaidya KS, Ismail A et al (2010) Homotypic gap junctional communication associated with metastasis suppression increases with PKA activity and is unaffected by PI3K inhibition. Cancer Res 70:10002–10011PubMedCrossRef

11.

DeWald DB, Torabinejad J, Samant RS et al (2005) Metastasis suppression by breast cancer metastasis suppressor 1 involves reduction of phosphoinositide signaling in MDA-MB-435 breast carcinoma cells. Cancer Res 65:713–717PubMed

12.

Vaidya KS, Harihar S, Stafford LJ et al (2008) Breast cancer metastasis suppressor-1 differentially modulates growth factor signaling. J Biol Chem 283:28354–28360PubMedCrossRef

13.

Cicek M, Fukuyama R, Welch DR et al (2005) Breast cancer metastasis suppressor 1 inhibits gene expression by targeting nuclear factor-kappaB activity. Cancer Res 65:3586–3595PubMedCrossRef

14.

Samant RS, Clark DW, Fillmore RA et al (2007) Breast cancer metastasis suppressor 1 (BRMS1) inhibits osteopontin transcription by abrogating NF-kappaB activation. Mol Cancer 6:6PubMedCrossRef

15.

Liu Y, Smith PW, Jones DR (2006) Breast cancer metastasis suppressor 1 functions as a corepressor by enhancing histone deacetylase 1-mediated deacetylation of RelA/p65 and promoting apoptosis. Mol Cell Biol 26:8683–8696PubMedCrossRef

16.

Samant RS, Seraj MJ, Saunders MM et al (2001) Analysis of mechanisms underlying BRMS1 suppression of metastasis. Clin Exp Metastasis 18:683–693CrossRef

17.

Phadke PA, Vaidya KS, Nash KT et al (2008) BRMS1 suppresses breast cancer experimental metastasis to multiple organs by inhibiting several steps of the metastatic process. Am J Pathol 172:809–817PubMedCrossRef

18.

Meehan WJ, Samant RS, Hopper JE et al (2004) Breast cancer metastasis suppressor 1 (BRMS1) forms complexes with retinoblastoma-binding protein 1 (RBP1) and the mSin3 histone deacetylase complex and represses transcription. J Biol Chem 279:1562–1569PubMedCrossRef

19.

Hurst DR, Xie Y, Vaidya KS et al (2008) Alterations of BRMS1–ARID4A interaction modify gene expression but still suppress metastasis in human breast cancer cells. J Biol Chem 283:7438–7444PubMedCrossRef

20.

Cicek M, Fukuyama R, Cicek MS et al (2009) BRMS1 contributes to the negative regulation of uPA gene expression through recruitment of HDAC1 to the NF-kappaB binding site of the uPA promoter. Clin Exp Metastasis 26:229–237PubMedCrossRef

21.

Samant RS, Debies MT, Shevde LA et al (2002) Identification and characterization of murine ortholog (Brms1) of breast cancer metastasis suppressor 1 (BRMS1). Int J Cancer 97:15–20PubMedCrossRef

22.

Samant RS, Debies MT, Hurst DR et al (2006) Suppression of murine mammary carcinoma metastasis by the murine ortholog of breast cancer metastasis suppressor 1 (Brms1). Cancer Lett 235:260–265PubMedCrossRef

23.

Richmond A, Su Y (2008) Mouse xenograft models vs. GEM models for human cancer therapeutics. Dis Model Mech 1:78–82PubMedCrossRef

24.

Welch DR (1997) Technical considerations for studying cancer metastasis in vivo. Clin Exp Metastasis 15:272–306PubMedCrossRef

25.

Guy CT, Cardiff RD, Muller WJ (1992) Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease. Mol Cell Biol 12:954–961PubMed

26.

Lin EY, Jones JG, Li P et al (2003) Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases. Am J Pathol 163:2113–2126PubMedCrossRef

27.

Hurst DR, Edmonds MD, Scott GK et al (2009) Breast cancer metastasis suppressor 1 BRMS1 up-regulates miR-146 that suppresses breast cancer metastasis. Cancer Res 69:1279–1283PubMedCrossRef

28.

Weidner N (1995) Current pathologic methods for measuring intratumoral microvessel density within breast carcinoma and other solid tumors. Breast Cancer Res Treat 36:169–180PubMedCrossRef

29.

Henrard D, Ross SR (1988) Endogenous mouse mammary tumor virus is expressed in several organs in addition to the lactating mammary gland. J Virol 62:3046–3049PubMed

30.

Schneider J, Gomez-Esquer F, Diaz-Gil G et al (2011) mRNA expression of the putative antimetastatic gene BRMS1 and of apoptosis-related genes in breast cancer. Cancer Genomics Proteomics 8:195–197PubMed

31.

Ladeda V, Adam AP, Puricelli L et al (2001) Apoptotic cell death in mammary adenocarcinoma cells is prevented by soluble factors present in the target organ of metastasis. Breast Cancer Res Treat 69:39–51PubMedCrossRef

32.

Cavanaugh PG, Nicolson GL (1989) Purification and some properties of a lung-derived growth factor that differentially stimulates the growth of tumor cells metastatic to the lung. Cancer Res 49:3928–3933PubMed

33.

Wyckoff JB, Wang Y, Lin EY et al (2007) Direct visualization of macrophage-assisted tumor cell intravasation in mammary tumors. Cancer Res 67:2649–2656PubMedCrossRef

34.

Wang W, Wyckoff JB, Goswami S et al (2007) Coordinated regulation of pathways for enhanced cell motility and chemotaxis is conserved in rat and mouse mammary tumors. Cancer Res 67:3505–3511PubMedCrossRef

35.

Grum-Schwensen B, Klingelhofer J, Grigorian M et al (2010) Lung metastasis fails in MMTV-PyMT oncomice lacking S100A4 due to a T-cell deficiency in primary tumors. Cancer Res 70:936–947PubMedCrossRef

36.

DeNardo DG, Barreto JB, Andreu P et al (2009) CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell 16:91–102PubMedCrossRef

37.

Yang L, Huang J, Ren X et al (2008) Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-1+CD11b+myeloid cells that promote metastasis. Cancer Cell 13:23–35PubMedCrossRef

38.

Wiseman BS, Werb Z (2002) Stromal effects on mammary gland development and breast cancer. Science (Washington, DC) 296:1046–1049CrossRef

39.

Bhowmick NA, Neilson EG, Moses HL (2004) Stromal fibroblasts in cancer initiation and progression. Nature 432:332–337PubMedCrossRef

40.

Lifsted T, Le Voyer T, Williams M et al (1998) Identification of inbred mouse strains harboring genetic modifiers of mammary tumor age of onset and metastatic progression. Int J Cancer 77:640–644PubMedCrossRef

41.

Qiu TH, Chandramouli GVR, Hunter KW et al (2004) Global expression profiling identifies signatures of tumor virulence in MMTV-PyMT-transgenic mice: correlation to human disease. Cancer Res 64:5973–5981PubMedCrossRef

42.

Zhang Z, Yamashita H, Toyama T et al (2006) Reduced expression of the breast cancer metastasis suppressor 1 mRNA is correlated with poor progress in breast cancer. Clin Cancer Res 12:6410–6414PubMedCrossRef

43.

Hicks DG, Yoder BJ, Short S et al (2006) Loss of BRMS1 protein expression predicts reduced disease-free survival in hormone receptor negative and HER2 positive subsets of breast cancer. Clin Cancer Res 12:6702–6708PubMedCrossRef

44.

Lombardi G, Di Cristofano C, Capodanno A et al (2006) High level of messenger RNA for BRMS1 in primary breast carcinomas is associated with poor prognosis. Int J Cancer 120:1169–1178CrossRef

45.

Metge BJ, Frost AR, King JA et al (2008) Epigenetic silencing contributes to the loss of BRMS1 expression in breast cancer. Clin Exp Metastasis 25:753–763PubMedCrossRef

46.

Frolova N, Edmonds MD, Bodenstine TM et al (2009) A shift from nuclear to cytoplasmic breast cancer metastasis suppressor 1 expression is associated with highly proliferative estrogen receptor-negative breast cancers. Tumour Biol 30:148–159PubMedCrossRef

Title: Ubiquitous Brms1 expression is critical for mammary carcinoma metastasis suppression via promotion of apoptosis
Authors: Leah M. Cook
Xuemei Cao
Alexander E. Dowell
Michael T. Debies
Mick D. Edmonds
Benjamin H. Beck
Robert A. Kesterson
Renee A. Desmond
Andra R. Frost
Douglas R. Hurst
Danny R. Welch
Publication date: 01-04-2012
Publisher: Springer Netherlands
Published in: Clinical & Experimental Metastasis / Issue 4/2012
Print ISSN: 0262-0898
Electronic ISSN: 1573-7276
DOI: https://doi.org/10.1007/s10585-012-9452-x

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2012

Distinct patterns of human medulloblastoma dissemination in the developing chick embryo nervous system

Subcutaneous passage increases cell aggressiveness in a xenograft model of diffuse large B cell lymphoma

Downregulation of protein tyrosine phosphatase PTPL1 alters cell cycle and upregulates invasion-related genes in prostate cancer cells

Tumor microenvironment: a main actor in the metastasis process

BMP signalling controls the malignant potential of ascites-derived human epithelial ovarian cancer spheroids via AKT kinase activation

Augmented autocrine bone morphogenic protein (BMP) 7 signaling increases the metastatic potential of mouse breast cancer cells

Keynote webinar | Spotlight on antibody–drug conjugates in cancer